MedTrace Logo

Outpatient Control-to-Range: System and Monitoring Testing

NCT01578980 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2014-09-16

Study results available
· View outcomes & findings →

Summary

A single arm, single treatment study is proposed to assess the feasibility of the AP Platform (cell phone + Control to Range system) outside of a hospital based clinical research center.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

DEVICE

Outpatient Control-to-Range

Subjects will spend two nights (\~42 hours) in a local hotel during which the AP Platform will be remotely monitored in an adjacent hotel room for validation that remote system monitoring can successfully occur.

Sponsors & Collaborators

  • Juvenile Diabetes Research Foundation

    collaborator OTHER

  • University of California, Santa Barbara

    collaborator OTHER

  • University of Virginia

    lead OTHER

Principal Investigators

  • Boris P. Kovatchev, Ph.D. · University of Virginia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01578980 on ClinicalTrials.gov